Worth reading
22Immaterial
Scored from 4 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Who is moving to which position
Resolved 11 May 2026Incoming appointee
2 itemsScheduled Appointment DateEffective 24 June 2026. The filing states that the changes have been provisionally decided.
Ito Atsushi (伊東 厚)
Previous positionDeputy General Manager, Sales Division
New positionExecutive Officer (Deputy General Manager, Sales Division)
Kobayashi Hideaki (小林 秀昭)
Previous positionDeputy Head of Administration Division
New positionExecutive Officer (Deputy General Manager, Administration Division)
Departing officer
2 itemsDate of departure24 June 2026
Seki Hiroto (関 浩人)Next role stated
Former PositionExecutive Officer (Head of Endocrine Business Promotion Office)
New position— (retiring)
Saito Junichi (齋藤 淳一)Next role stated
Former PositionDirectors
New position— (retiring)
“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.
Whether the incumbent will remain in office (whether they will retain their position)
There is no indication that either will remain on the Board of Directors.
| Item | Details |
|---|---|
| Resolution date | 11 May 2026 |
| Scheduled Appointment Date | Effective 24 June 2026. The filing states that the changes have been provisionally decided. |
| Date of departure | 24 June 2026 |
| Name of appointee | Ito Atsushi (伊東 厚), Kobayashi Hideaki (小林 秀昭) |
| Appointee's new position | Executive Officer (Deputy General Manager, Sales Division), Executive Officer (Deputy General Manager, Administration Division) |
| Appointee's previous position | Deputy General Manager, Sales Division, Deputy Head of Administration Division |
| Name of departing officer | Seki Hiroto (関 浩人), Saito Junichi (齋藤 淳一) |
| Former position of departing officer | Executive Officer (Head of Endocrine Business Promotion Office), Directors |
| New position of departing officer | — (retiring), — (retiring) |
| Whether the incumbent will remain in office | There is no indication that either will remain on the Board of Directors. |
Items this document does not state (11)
Appointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeReason for departureReason for changeReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No reason for the changes is provided.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.